Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent

Nature Reviews Nephrology 12, 128 (2016). doi:10.1038/nrneph.2015.217 Authors: Hillel Sternlicht & George L. Bakris The effects of SGLT2 inhibitors on lowering blood pressure are well characterized, but data now demonstrate their enhanced blood pressure-lowering capacity when combined with dual antihypertensive therapy. Specifically, blood pressure was markedly reduced when dapagliflozin was administered to patients receiving a renin–angiotensin system blocker plus a calcium antagonist or β-blocker.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Tags: News and Views Source Type: research